Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy

Neuropsychopharmacology

Volumn 23, Issue 5, 2000, Pages 528-538

  Okura, Mutsumi ^a,b   Riehl, Joyce ^a   Mignot, Emmanuel ^a   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KOBE UNIVERSITY   (Japan)

Author keywords

Cataplexy; Dopaminergic System; Narcolepsy; REM sleep; Sulpiride

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATAPLEXY; CONTROLLED STUDY; DOG; DOPAMINERGIC SYSTEM; FEMALE; MALE; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; REM SLEEP; SLEEP DISORDER;

ANIMAL; AROUSAL; CATAPLEXY; DOGS; DOPAMINE ANTAGONISTS; ELECTROENCEPHALOGRAPHY; FEMALE; MALE; NARCOLEPSY; RECEPTORS, DOPAMINE D2; SLEEP, REM; SULPIRIDE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033797492     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00140-8     Document Type: Article

References (56)

1. Akimoto H., Honda Y., Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Sys. 21:1960;704-706.
2. Aldrich M.S. Narcolepsy. Neurology. 42:1992;34-43.
3. Aston-Jones G., Bloom F.E. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci. 1:1981;876-886.
4. Baker T.L., Dement W.C. Canine narcolepsy-cataplexy syndrome. evidence for an inherited monoaminergic-cholinergic imbalance McGinty D.J., Drucker-Colin R., Morrison A., Parmeggiani P.L. Brain Mechanisms of Sleep. 1985;199-233 Raven Press, New York.
5. Baldessarini R.J. How do antidepressants work? Davis J.M., Mass J.W. The Affective Disorders. 1983;243-260 American Psychiatric Press, Washington, DC.
6. Borenstein P., Champion C., Cujo P., Gekiere F., Olivenstein C., Kramarz P. An original psychotropic drug. sulpiride Sem Hop. 45:1969;1301-1314.
7. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice. molecular genetics of sleep regulation Cell. 98:1999;437-451.
8. Daly S.A., Waddington J.L. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology. 32:1993;509-510.
9. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins. hypothalamus-specific peptides with neuroexcitatory activity Proc Natl Acad Sci USA. 95:1998;322-327.
10. Diagnostic Classification Steering Committee, Thorpy MJ, Chairman (1990): ICSD - International Classification of Sleep Disorders: Diagnostic and Coding Manual. Rochester, Minnesota: American Sleep Disorders Association.
11. Guilleminault C. Narcolepsy syndrome. Kryger M.H., Roth T., Dement W.C. Principles and Practice of Sleep Medicine. 1994;549-561 W.B. Saunders Company, Philadelphia.
12. Guilleminault C., Wilson R.A., Dement W.C. A study on cataplexy. Arch Neurol. 31:1974;255-261.
13. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., Benham C.D., Taylor S.G., Routledge C., Hemmati P., Munton R.P., Ashmeade T.E., Shah A.S., Hatcher J.P., Hatcher P.D., Jones D.N., Smith M.I., Piper D.C., Hunter A.J., Porter R.A., Upton N. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA. 96:1999;10911-10916.
14. Honda K., Riehl J., Mignot E., Nishino S. Dopamine D3 agonists into the substratia nigra aggravates cataplexy but does not modify sleep. Neuroreport. 10:1999;3111-3118.
15. Kaitin K.I., Kilduff T.S., Dement W.C. Sleep fragmentation in genetically narcoleptic dogs. Sleep. 9:1986;116-119.
16. Levesque D., Diaz J., Pilon C., Martres M.P., Giros B., Souil E., Schott D., Morgat J.L., Schwartz J.C., Sokoloff P. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2- aminotetralin. Proc Natl Acad Sci USA. 89:1992;8155-8159.
17. Lim R.K.S., Liu C.-N., Moffitt R.L. A Stereotaxic Atlas of the Dog's Brain. 1960;Thomas Books, Springfield, IL.
18. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 98:1999;365-376. [see comments].
19. McClelland G.R., Cooper S.M., Pilgrim A.J. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol. 30:1990;795-803.
20. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience. 79:1997;323-327.
21. Mignot E., Guilleminault C., Bowersox S., Fruhstorfer B., Nishino S., Maddaluno J., Ciaranello R., Dement W.C. Central alpha-1 adrenoceptor subtypes in narcolepsy-cataplexy. a disorder of REM sleep Brain Res. 490:1989;186-191.
22. Mignot E., Renaud A., Nishino S., Arrigoni J., Guilleminault C., Dement W.C. Canine cataplexy is preferentially controlled by adrenergic mechanisms. evidence using monoamine selective uptake inhibitors and release enhancers Psychopharmacology. 113:1993;76-82.
23. Miller J.D., Farber J., Gatz P., Roffwarg H., German D.C. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res. 273:1983;133-141.
24. Mitler M.M., Dement W.C. Sleep studies on canine narcolepsy. pattern and cycle comparisons between affected and normal dogs Electroencephalogr Clin Neurophysiol. 43:1977;691-699.
25. Nishino S., Arrigoni J., Shelton J., Dement W.C., Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 16:1993;706-712. a.
26. Nishino S., Arrigoni J., Valtier D., Miller J.D., Guilleminault C., Dement W.C., Mignot E. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci. 11:1991;2666-2671.
27. Nishino S., Fruhstorfer B., Arrigoni J., Guilleminault C., Dement W.C., Mignot E. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther. 264:1993;1079-1084. b.
28. Nishino S., Haak L., Shepherd H., Guilleminault C., Sakai T., Dement W.C., Mignot E. Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. J Pharmacol Exp Ther. 253:1990;1145-1152.
29. Nishino S., Honda K., Riehl J., Mignot E. Extracellular single unit recordings of dopaminergic neurons in the ventral tegmental area in narcoleptic dobermans. Sleep. 23S2:2000;A1. a (APSS abstract).
30. Nishino S., Mao J., Sampathkumaran R., Shelton J., Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Research Online. 1:1998;49-61. a.
31. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 52:1997;27-78.
32. Nishino S., Riehl J., Hong J., Kwan M., Honda K., Mignot E. REM sleep, but not cataplexy, is controlled by a 30-minute normal ultradian rhythm in narcoleptic canines. Sleep. 22S:1999;S2. (APSS abstract).
33. Nishino S., Riehl J., Mignot E. Effects of dopaminergic and noradrenergic uptake inhibitors on dopaminergic D3 agonist-included cataplexy. Sleep. 21S:1998;S181. b (APSS abstract).
34. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 355:2000;39-40. b.
35. Nishino S., Tafti M., Reid M.S., Shelton J., Siegel J.M., Dement W.C., Mignot E. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain. implication for the pathophysiology of canine narcolepsy J Neurosci. 15:1995;4806-4814.
36. Nissbrandt N., Engberg G., Pileblad E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Naunyn-Schmiedeberg's Arch Pharmacol. 344:1991;16-28.
37. Okura M., Honda K., Riehl J., Mignot E., Nishino S. Roles of diencephalic dopaminergic cell groups in regulation of cataplexy in canine narcolepsy. Sleep. 22S:1999;S1. (APSS abstract).
38. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 18:1998;9996-10015.
39. Piercey M.F., Hoffmann W.E., Smith M.W., Hyslop D.K. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist. comparison to other dopamine receptor agonists Eur J Pharmacol. 312:1996;35-44.
40. Reid M.S., Nishino S., Tafti M., Siegel J.M., Dement W.C., Mignot E. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Exp Neurol. 151:1998;89-104.
41. Reid M.S., Tafti M., Nishino S., Sampathkumaran R., Siegel J.M., Dement W.C., Mignot E. Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res. 733:1996;83-100.
42. Roth B., Bruhova S., Lehovsky M. REM sleep and NREM sleep in narcolepsy and hypersomnia. Electroenceph Clin Neurophysiol. 26:1969;176-182.
43. Scherschlicht R., Polc P., Schneeberger J., Steiner M., Haefely W. Selective supression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. Adv Biochem Psychopharmacol. 31:1982;359-364.
44. Schneider E., Ziegler B., Maxion H., Badawi M. Long- and short-term effects of sulpiride on sleep-EEG of man. Arzneimittelforschung. 24:1974;990-993.
45. Schneider E., Ziegler B., Maxion H., Badawi M. The influence of sulpirid on sleep. Results of polygraphic night sleep recordings. Pharmakopsychiatr Neuropsychopharmakol. 8:1975;90-98.
46. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., Oblin A., Gonon F., Carter C., Benavides J., Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 280:1997;83-97.
47. Schrader H., Bendixen-Markset A.C., Treidene H.E. The treatment of accessory symptoms in narcolepsy. a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo Acta Neurol Scand. 74:1986;297-303.
48. Siegel J.M., Nienhuis R., Fahringer H., Paul R., Shiromani P., Dement W.C., Mignot E., Chiu C. Neuronal activity in narcolepsy. identification of cataplexy related cells in the medial medulla Science. 262:1991;1315-1318.
49. Siegel J.M., Nienhuis R., Fahringer H.M., Chiu C., Dement W.C., Mignot E., Lufkin R. Activity of medial mesopontine units during cataplexy and sleep-waking states in the narcoleptic dog. J Neurosci. 13:1992;1640-1646.
50. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
51. Takahashi Y. Narcoleptic syndrome and paradoxical sleep. Saishin-Igatu. 26:1971;98-105.
52. Thorpy M.J., Goswami M. Treatment of narcolepsy. Thorpy M.J. Handbook of Sleep Disorders. 1990;235-258 Marcel Dekker, Inc, New York.
53. Trulson M.E. Activity of dopamine-containing substantia nigra neurons in freely moving cats. Neurosci Biobehav Rev. 9:1985;283-297.
54. Trulson M.E., Jacobs B.L. Raphe unit activity in freely moving cats. correlation with level of behavioral arousal Brain Res. 163:1979;135-150.
55. Wagstaff A., Fitton A., Benfield P. Sulpiride; a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in schizophrenia. CNS Drugs. 2:1994;313-333.
56. Wu M.F., Gulyani S.A., Yau E., Mignot E., Phan B., Siegel J.M. Locus coeruleus neurons. cessation of activity during cataplexy Neuroscience. 91:1999;1389-1399.